- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06558669
Effect of Sugarcane Juice on Liver Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized controlled trial (RCT) is designed to evaluate the impact of sugarcane juice on liver health in patients diagnosed with liver-related conditions, including cirrhosis, hepatitis, and fatty liver disease. The study aims to assess whether sugarcane juice, administered in varying dosages, has a therapeutic effect on liver enzyme levels and overall liver function.
Study Design
This is an interventional study using a randomized controlled trial (RCT) design. Participants will be randomly assigned to one of four groups: three treatment groups and one control group. The treatment groups will receive daily doses of sugarcane juice at 170mL, 230mL, and 300mL, respectively, along with their prescribed medicine, for a duration of three months. The control group will receive no sugarcane juice but will continue their prescribed medication regimen.
Intervention Details
Control Group: Receives no sugarcane juice, only prescribed medication. Group 1: Receives 170mL of sugarcane juice daily along with prescribed medication.
Group 2: Receives 230mL of sugarcane juice daily along with prescribed medication.
Group 3: Receives 300mL of sugarcane juice daily along with prescribed medication.
Duration of the Study
The study will span three months, during which participants' liver health will be monitored at regular intervals.
Outcome Measures
Primary Outcome Measures:
Levels of liver enzymes: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Total Bilirubin.
Secondary Outcome Measures:
Changes in liver-related symptoms, including jaundice, abdominal pain, fatigue, and nausea.
Sample Size
The study will enroll a total of 400 participants. The participants will be divided into four groups:
Control Group: 100 participants Group 1: 100 participants Group 2: 100 participants Group 3: 100 participants
Inclusion and Exclusion Criteria
Inclusion Criteria:
Patients diagnosed with liver disease, including but not limited to cirrhosis, hepatitis, or fatty liver disease.
Age group 20-60 years. Symptoms criteria based on liver disease include jaundice, abdominal pain, fatigue, nausea, and elevated liver enzymes (ALT, AST) as per standard diagnostic criteria.
Exclusion Criteria:
Patients younger than 20 years or older than 60 years. Patients with a history of other chronic conditions that may interfere with liver function, such as chronic kidney disease or heart failure.
Patients who have undergone liver transplantation. Patients currently participating in another clinical trial related to liver disease.
Pregnant or breastfeeding women.
Statistical Analysis Plan
The data will be analyzed using SPSS (version 27). A Two-Way ANOVA will be used to compare the effects of different dosages of sugarcane juice on liver enzyme levels across the treatment groups and control group. Post hoc analysis will be conducted using Tukey's Honest Significant Difference (HSD) test to identify specific group differences.
Quality Assurance Measures
Data Validation: Rigorous input checks, automated testing, and manual reviews will be implemented to ensure data accuracy.
Site Monitoring: Real-time monitoring tools will be employed to track site performance and swiftly identify any data issues.
Auditing: Regular audits will be performed to ensure compliance with the study protocol and to maintain the integrity of the data.
Handling Missing Data
Data Imputation: Both simple and advanced methods will be employed to impute missing data, ensuring the robustness of the dataset.
Data Cleansing: Consistency checks and outlier detection methods will be implemented to correct data errors.
User Feedback: Tools will be provided to allow users to report and correct missing or inconsistent data promptly.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab
-
Rawalpindi, Punjab, Pakistan, 43600
- Asif Ahmad
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients diagnosed with liver disease, Age group 20 to 60years Symptoms criteria based on liver disease include jaundice, abdominal pain, fatigue, nausea, and elevated liver enzymes (ALT, AST) as per standard diagnostic criteria.
Exclusion Criteria:
Patients younger than 20 years or older than 60 years. Pregnant or breastfeeding women Patients who have undergone liver transplantation. Patients with a history of other chronic conditions that may interfere with liver function, such as chronic kidney disease or heart failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control Group
There are 100 participants in this arm and will only consume their prescribed medicines.
|
|
|
Experimental: Treatment 1
There are 100 participants in this arm who will consume 170mL of fresh sugarcane juice and take their prescribed medicines.
|
Fresh sugarcane juice in different doses will be given to liver patients for 90 days
|
|
Experimental: Treatment 2
There are 100 participants in this arm who will consume 230mL of fresh sugarcane juice and take their prescribed medicines.
|
Fresh sugarcane juice in different doses will be given to liver patients for 90 days
|
|
Experimental: Treatment 3
There are 100 participants in this arm who will consume 300mL of fresh sugarcane juice and take their prescribed medicines.
|
Fresh sugarcane juice in different doses will be given to liver patients for 90 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver Health Status
Time Frame: ["1 Month" at study commencement (Phase 1)]
|
Liver health status will assessed through liver function tests including, ALT, AST, ALP, and Total Bilirubin in Phase 1.
|
["1 Month" at study commencement (Phase 1)]
|
|
LIver Health Status
Time Frame: [Termination of Phase 2(intervention period), "3 Month"]
|
Liver health status will assessed through liver function tests including, ALT, AST, ALP, and Total Bilirubin in Phase 2 after completion of three month intervention
|
[Termination of Phase 2(intervention period), "3 Month"]
|
|
LIver Health Status
Time Frame: [Termination of Phase 3 (Washout period), "1 Month"]
|
Liver health status will assessed through liver function tests including, ALT, AST, ALP, and Total Bilirubin in Phase 3 which is wash-out time
|
[Termination of Phase 3 (Washout period), "1 Month"]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dietary Pattern Analysis
Time Frame: [Through studyy compeletion, an avaerage of 9 month]
|
Dietary patterns will be analyzed using a Food Frequency Questionnaire (FFQ) to evaluate the patients' intake of various food groups.
This will include an assessment of the frequency, portion sizes, and overall dietary diversity.
The aim is to correlate dietary habits with the study's primary outcomes.
|
[Through studyy compeletion, an avaerage of 9 month]
|
|
Dietary Pattern Assessment
Time Frame: [Through studyy compeletion, an avaerage of 9 month]
|
A Food Frequency Questionnaire (FFQ) will be administered to assess the dietary patterns of the patients.
This questionnaire will capture the frequency, portion size, and types of food consumed over the study period.
The collected data will be used to analyze the relationship between dietary patterns and the primary outcomes of the study.
|
[Through studyy compeletion, an avaerage of 9 month]
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAURwI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver; Disease, Inflammatory
-
Shanghai East HospitalDongfang Hospital Affiliated to Tongji University; Shanghai Pudong New Area...RecruitingInflammatory Bowel Disease (IBD) | Metabolic Dysfunction Associated Fatty Liver DiseaseChina
-
University of North Carolina, Chapel HillUniversity of North Carolina, GreensboroCompletedFatty LiverUnited States
-
King Edward Medical UniversityCompletedInflammatory Bowel Diseases | Chronic Liver DiseasePakistan
-
Assiut UniversityUnknownInflammatory Bowel Disease Patients
-
Centre Hospitalier Universitaire Saint PierreRecruitingInflammatory Bowel Diseases | NAFLD | Fibrosis, Liver | SteatosisBelgium
-
Children's Mercy Hospital Kansas CityCompletedInflammatory Bowel Diseases | Methotrexate | Liver FibrosesUnited States
-
Tel-Aviv Sourasky Medical CenterTerminatedFatty Liver | Inflammatory Bowel DiseaseIsrael
-
Chikara TashiroCompletedInflammatory Bowel Disease | Pancreas Disease | Hepatobiliary DiseaseJapan
-
Cliniques universitaires Saint-Luc- Université...CompletedLiver Diseases | Liver Cirrhosis | Sepsis | Critical IllnessBelgium
-
Inonu UniversityUnknownInflammatory Response | Liver Transplant; ComplicationsTurkey
Clinical Trials on Fresh Sugarcane juice
-
Loma Linda UniversityCompletedBlood PressureUnited States
-
Indonesia UniversityIndonesia-MoHCompleted
-
Jordan University of Science and TechnologyCompletedPatients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)Jordan
-
Rehman Medical Institute - RMINot yet recruitingGlycemic Index and Glycemic LoadPakistan
-
University of HohenheimUnknown
-
Bangladesh Agricultural UniversityCompletedGastrointestinal Diseases | Foodborne Diseases | Escherichia Coli | Microbial Contamination | Street Vended Foods | S. Aureus | Total Viable CountBangladesh
-
Xinqiao Hospital of ChongqingUnknown
-
Oxford Brookes UniversityNot yet recruitingHypertension | Type 2 Diabetes Mellitus | Autonomic Nervous System DiseasesUnited Kingdom
-
University of ArizonaArizona State University; El Rio Community Health CenterEnrolling by invitationDiabetes Mellitus, Type 2United States